Loading
NYSEConsumer DefensiveHousehold & Personal Products
Latest quote
$17.70
−$0.03 · -0.17%
Kenvue Inc. functions as a global leader in the consumer health sector. The company structures its operations across three primary divisions: Self Care, Skin Health and Beauty, and Essential Health. Within the Self Care unit, it offers a diverse range of products for common conditions like coughs, colds, and allergies, in addition to pain relief, digestive health, and smoking cessation aids, featuring prominent brands such as Tylenol, Nicorette, and Zyrtec. The Skin Health and Beauty segment delivers various solutions for facial, body, hair, and sun protection, recognized under popular labels including Neutrogena, Aveeno, and OGX. Moreover, the Essential Health category provides oral hygiene, infant care, feminine wellness, and wound treatment products, marketed through esteemed brands like Listerine, Johnson's, Band-Aid, and Stayfree. Established in 2022, Kenvue Inc. maintains its corporate headquarters in Skillman, New Jersey, and operates as a subsidiary of Johnson & Johnson.
Previous close
$17.70
−$0.03 · -0.17%
Regular session · ET · Market data may be delayed.
Kenvue Inc. functions as a global leader in the consumer health sector. The company structures its operations across three primary divisions: Self Care, Skin Health and Beauty, and Essential Health. Within the Self Care unit, it offers a diverse range of products for common conditions like coughs, colds, and allergies, in addition to pain relief, digestive health, and smoking cessation aids, featuring prominent brands such as Tylenol, Nicorette, and Zyrtec. The Skin Health and Beauty segment delivers various solutions for facial, body, hair, and sun protection, recognized under popular labels including Neutrogena, Aveeno, and OGX. Moreover, the Essential Health category provides oral hygiene, infant care, feminine wellness, and wound treatment products, marketed through esteemed brands like Listerine, Johnson's, Band-Aid, and Stayfree. Established in 2022, Kenvue Inc. maintains its corporate headquarters in Skillman, New Jersey, and operates as a subsidiary of Johnson & Johnson.
Day range
Current $17.70
52-week range
Current $17.70
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
84
Deep Value
Sentiment
54
Mixed
Risk
23
Moderate Risk
Momentum
49
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Kenvue Inc. functions as a global leader in the consumer health sector. The company structures its operations across three primary divisions: Self Care, Skin Health and Beauty, and Essential Health. Within the Self Care unit, it offers a diverse range of products for common conditions like coughs, colds, and allergies, in addition to pain relief, digestive health, and smoking cessation aids, featuring prominent brands such as Tylenol, Nicorette, and Zyrtec. The Skin Health and Beauty segment delivers various solutions for facial, body, hair, and sun protection, recognized under popular labels including Neutrogena, Aveeno, and OGX. Moreover, the Essential Health category provides oral hygiene, infant care, feminine wellness, and wound treatment products, marketed through esteemed brands like Listerine, Johnson's, Band-Aid, and Stayfree. Established in 2022, Kenvue Inc. maintains its corporate headquarters in Skillman, New Jersey, and operates as a subsidiary of Johnson & Johnson.
Day range
Current $17.70
52-week range
Current $17.70
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 15.12B USD | 15.46B USD | 15.44B USD | 14.95B USD | 15.05B USD |
| Cost of goods sold | 6.33B USD | 6.5B USD | 6.8B USD | 6.67B USD | 6.64B USD |
| Gross profit | 8.79B USD | 8.96B USD | 8.64B USD | 8.29B USD | 8.42B USD |
| Research and development | 382M USD | — | — | — | — |
| Selling, general, and administrative | 6.09B USD | 6.03B USD | 6.14B USD | 5.63B USD | 5.48B USD |
| Operating expenses | 6.09B USD | 7.12B USD | 6.13B USD | 5.61B USD | 5.5B USD |
| Interest income | — | 53M USD | 108M USD | — | — |
| Interest expense | 379M USD | 431M USD | 358M USD | — | — |
| Depreciation and amortization | 557M USD | 622M USD | 627M USD | 644M USD | 731M USD |
| Operating income | 2.7B USD | 1.84B USD | 2.51B USD | 2.68B USD | 2.92B USD |
| Net income | 1.47B USD | 1.03B USD | 1.66B USD | 2.06B USD | 2.08B USD |
Company facts updated Oct 11, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Average target
$19.50
10.17% upsideFunds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P 500 ETF1557.T65.96B0.05%129.35T JPY0.09%¥122,850+0.12%
Vanguard Morningstar Total Stock Market ETFVTI1.15B0.05%2.3T USD0.03%$381.94+0.63%
Vanguard S&P 500 ETFVOO963.09M0.05%1.8T USD0.03%$715.59+0.61%
Vanguard Morningstar Mid-Cap ETFVO784.1M0.35%226.4B USD0.03%$81.14+0.92%
iShares Core S&P 500 ETFIVV452.72M0.05%896.44B USD0.03%$781.97+0.60%
State Street SPDR S&P 500 ETFSPY416.71M0.05%817.2B USD0.09%$778.57+0.60%
Vanguard Morningstar Value ETFVTV346.38M0.13%262.4B USD0.03%$220.59+0.44%
State Street SPDR S&P Dividend ETFSDY309.87M1.49%20.75B USD0.35%$149.04-0.22%State Street SPDR S&P 500 ETF1557.TVanguard Morningstar Total Stock Market ETFVTIVanguard S&P 500 ETFVOOVanguard Morningstar Mid-Cap ETFVOiShares Core S&P 500 ETFIVVState Street SPDR S&P 500 ETFSPYVanguard Morningstar Value ETFVTVState Street SPDR S&P Dividend ETFSDYAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
